ADC Therapeutics SA

ADCT

Exchange: NYSE
Industry: Pharmaceutical Preparations
SEC CIK: 0001771910

SEC filings (opens in a new tab)

No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $171.1M
Insider buysOpen market, last 90 days: 0
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, −4 vs. previous quarter: 113
13F valueReported value at the end of Q2 2026: $86.3M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $81.4M; +14.9% year over year
Net income, FY2025: -$142.6M; No comparable prior period
Free cash flow, FY2025: -$141.4M; No comparable prior period
Revenue, Q3 FY2026: $21.7M; +32.2% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $142.6M (175.3% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 6.43M; Shares sold short
Change: +88.0K; +1.4% vs. previous
Days to cover: 6.66; At average daily volume

Superinvestors holding ADCT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ADCT at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by ADC Therapeutics SA insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Apr 2, 2026 (view filing)9:00 PM ET	Mar 31-Apr 2	2 days	Redmile Group, LLC and 2 others10% Owner	SSale	−3.00M	$3.34	−$10.0M	−19.1%12.7M after	3 lots
Apr 2, 2026 (view filing)9:00 PM ET	Mar 31-Apr 2	2 days	Redmile Group, LLC and 2 others10% Owner	SSale	−2.88M	$3.34	−$9.62M	−21.9%10.3M after	3 lots
Oct 28, 2025 (view filing)9:00 PM ET	Oct 27	1 day	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Share	+3.85M	$3.90	+$15.0M	–3.85M after	Derivative
Oct 28, 2025 (view filing)9:00 PM ET	Oct 27	1 day	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Share	+3.85M	$3.90	+$15.0M	–3.85M after	Derivative
Jun 13, 2025 (view filing)6:00 PM ET	Jun 11	2 days	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Share	+15.7M	$3.43	+$54.0M	–15.7M after	Derivative
Jun 13, 2025 (view filing)6:00 PM ET	Jun 11	2 days	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Share	+12.5M	$3.43	+$42.8M	–12.5M after	Derivative
Dec 13, 2024 (view filing)9:00 PM ET	Dec 11	2 days	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Shares, par value CHF 0.08 per share	+100.0K	$3.05	+$304.5K	+0.6%15.7M after	2 lots
Dec 13, 2024 (view filing)9:00 PM ET	Dec 11	2 days	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Shares, par value CHF 0.08 per share	+100.0K	$3.05	+$304.5K	+0.8%13.1M after	2 lots
Dec 6, 2024 (view filing)9:00 PM ET	Dec 4	2 days	Redmile Group, LLC and 2 others10% Owner	SSaleCommon Shares, par value CHF 0.08 per share	−25.4K	$2.07	−$52.5K	−0.2%15.6M after
Jul 3, 2024 (view filing)8:00 PM ET	Jul 1	2 days	Redmile Group, LLC and 2 others10% Owner	PPurchaseCommon Shares, par value CHF 0.08 per share	+400.0K	$2.81	+$1.12M	+2.6%15.7M after

Top 10 13F holders, Q2 2026

See all 113 holders

The largest institutional positions in ADC Therapeutics SA at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ADCT in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Nantahala Capital Management, LLC	12,326,184	$13.2M	0.80%	+6,728,751+120.2%	Added
Redmile Group, LLC	11,526,710	$12.3M	0.83%	−3,943,792−25.5%	Reduced
TCG Crossover Management, LLC	11,390,175	$12.2M	0.29%	00.0%	Unchanged
Prosight Management, LP	7,824,749	$8.37M	1.44%	−475,251−5.7%	Reduced
BlackRock, Inc.	7,020,093	$7.51M	0.00%	+769,346+12.3%	Added
Point72 Asset Management, L.P.	3,649,144	$3.90M	0.01%	+267,015+7.9%	Added
Morgan Stanley	3,051,173	$3.26M	0.00%	−761,409−20.0%	Reduced
Millennium Management LLC	2,899,535	$3.10M	0.00%	−219,619−7.0%	Reduced
Citadel Advisors LLC	2,053,316	$2.20M	0.00%	+1,653,595+413.7%	Added
Goldman Sachs Group Inc	1,914,424	$2.05M	0.00%	+261,398+15.8%	Added

Holders of 5% or more of ADCT

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of ADC Therapeutics SA.

Largest holders of ADCT from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Bain Capital Life Sciences Opportunities IV, L.P.	13G	9.99%14.8M shares	New	Oct 29, 20261 filing	Oct 29, 2026	SEC
Redmile Group, LLC	13G/A	9.90%12.7M shares	0.00 ppfrom 9.90%	Feb 16, 20219 filings	Apr 24, 2026	SEC
Nantahala Capital Management, LLC	13G	9.69%12.3M shares	New	Aug 14, 20261 filing	Aug 14, 2026	SEC
HPWH TH AG	13G/A	9.61%9.79M shares	–	May 19, 20251 filing	May 19, 2025	SEC
TCG Crossover GP II, LLC	13G	9.20%11.4M shares	New	Feb 17, 20261 filing	Feb 17, 2026	SEC

Politician trades

All politician trades in ADCT

1 member of Congress reported 1 trade in ADC Therapeutics SA since 2020. Newest filings:

Latest politician trades in ADCT
Filed	Politician	Type	Amount
Mar 22, 2025	Ashley Moody Senate · FL	Sell (full)	$1K-$15K

Ashley Moody
Senate · FL · Mar 22, 2025
Sell (full)$1K-$15K